Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Sells $309,400.00 in Stock

Key Points

• Xeris Biopharma Director Dawn Halkuff sold 42,500 shares of stock at an average price of $7.28, resulting in a transaction totaling $309,400 and a 26.98% decrease in the director's ownership.
• The company's shares traded down 0.3% to $7.28, with a market capitalization of $1.17 billion and a price-to-earnings ratio of -34.64.
• Analyst ratings for Xeris Biopharma have improved, with Oppenheimer raising their price target from $6.00 to $7.00, and several firms assigning a buy or strong buy rating.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) Director Dawn Halkuff sold 42,500 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $7.28, for a total value of $309,400.00. Following the completion of the transaction, the director directly owned 115,000 shares in the company, valued at approximately $837,200. This trade represents a 26.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock traded down $0.21 during midday trading on Monday, reaching $7.48. 705,626 shares of the company's stock traded hands, compared to its average volume of 2,563,884. The company has a market cap of $1.21 billion, a PE ratio of -35.59 and a beta of 0.65. The stock has a 50 day moving average of $5.23 and a 200-day moving average of $4.72. Xeris Biopharma Holdings, Inc. has a 12 month low of $2.48 and a 12 month high of $7.79.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The business had revenue of $67.71 million for the quarter, compared to the consensus estimate of $64.58 million. On average, equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on XERS. HC Wainwright assumed coverage on Xeris Biopharma in a research note on Tuesday, August 12th. They issued a "buy" rating and a $10.00 price target on the stock. Oppenheimer lifted their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Finally, Wall Street Zen raised Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $6.58.

Institutional Trading of Xeris Biopharma

Several large investors have recently bought and sold shares of XERS. Vanguard Group Inc. raised its holdings in Xeris Biopharma by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company's stock worth $26,778,000 after purchasing an additional 133,738 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Xeris Biopharma by 166.2% during the 4th quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company's stock valued at $3,537,000 after purchasing an additional 651,481 shares during the period. Geode Capital Management LLC grew its stake in shares of Xeris Biopharma by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company's stock valued at $11,364,000 after purchasing an additional 17,956 shares during the period. Wells Fargo & Company MN grew its position in shares of Xeris Biopharma by 38.7% during the 4th quarter. Wells Fargo & Company MN now owns 79,036 shares of the company's stock valued at $268,000 after acquiring an additional 22,050 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in shares of Xeris Biopharma by 1,496.3% during the 4th quarter. Russell Investments Group Ltd. now owns 17,974 shares of the company's stock valued at $61,000 after acquiring an additional 16,848 shares during the period. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.